Prostate cancer
GU011
A PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL OF PROSTATE OLIGOMETASTATIC RADIOTHERAPY WITH OR WITHOUT ANDROGEN DEPRIVATION THERAPY IN OLIGOMETASTATIC PROSTATE CANCER (NRG PROMETHEAN)
Trial overview
Topic
NRG-GU011
Disease
Prostate cancer
Description
Compare conventional radiological progression-free survival (rPFS) for positron emission tomography (PET)-detected, biochemically recurrent, oligometastatic, castration-sensitive prostate cancer patients treated with SABR plus placebo vs. SABR plus relugolix.
Contact
Physicians
Frank A. Vicini
MD, FACR, FASTRO, FABS
Radiation Oncologist
Farmington Hills (Radiation oncology) +2
Eduardo B. Fernandez
MD, PhD, DABR, FACRO, FASTRO
Radiation Oncologist
Aventura (Radiation oncology) +3
